Sartorius Stedim Biotech
€209.00Change from previous close: +1.36%Absolute change: +€2.80
Valuation
Data as of October 2, 2026
Valuation multiples
- Market cap
- €20.33B
- Enterprise value
- €22.18B
- P/E (trailing 12 months)
- 69.4
- Forward P/E
- 34.8
- PEG
- 1.53
- Price/book
- 4.78
- Price/sales
- 6.77
- EV/EBITDA
- 27.2
- EV/revenue
- 7.38
Profitability and growth
- Gross margin
- 44.9%
- Operating margin
- 20.1%
- Net margin
- 9.7%
- ROE
- 7.1%
- ROA
- 4.4%
- Revenue growth (year over year)
- 2.8%
- Earnings growth (year over year)
- 37.1%
Financial health
- Total cash
- €204.2M
- Total debt
- €2.4B
- Debt/equity
- 0.57
- Current ratio
- 1.16
- Quick ratio
- 0.48
Dividends
- Annual dividend per share
- €0.69
- Dividend yield
- 0.3%
- Payout ratio
- 22.9%
- Ex-dividend date
- March 31, 2026
Analysts and estimates
- Average price target
- €237.29
- Median price target
- €239.50
- High price target
- €262.00
- Low price target
- €210.00
- Analysts with a price target
- 14
- Consensus
- Strong buy
- Forward EPS
- €6.00
- EPS estimate, current year
- €4.99
Shares and trading
- Beta
- 1.15
- Average volume
- 86.94K
- Shares outstanding
- 97.29M
- Float
- 27.62M
- Institutional ownership
- 11.9%
- Insider ownership
- 71.5%